• Regeneron Pharmaceuticals, Inc.

    Eylea (aflibercept) has received marketing approval in Japan for the treatment of myopic choroidal neovascularization (CNV).

    Already approved in Japan for wet AMD and macular edema secondary to central retinal vein occlusion (CRVO), Regeneron is pursuing additional approvals for diabetic macular edema (DME) and macular edema secondary to branch retinal vein occlusion (BRVO).

    Eylea is approved in the United States, European Union and other countries for wet AMD, macular edema following CRVO, and DME. U.S. and EU approval is being sought for macular edema following BRVO.